Table 4:
Associations between clinically ascertained and self-report PN,1 by sex
| Females (N=1436) | Males (N=1497) | ||||
|---|---|---|---|---|---|
|
| |||||
| PRR (95% CI) | P-value | PRR (95% CI) | P-value | ||
|
| |||||
| Decreased sense of touch or feeling in hands, fingers, arms, or legs | |||||
|
| |||||
| Yes | 6.43 (4.25–9.72) | <.001 | 6.06 (3.84–9.54) | <.001 | |
|
| |||||
| No | Ref | Ref | |||
|
| |||||
| Abnormal sensation in arms, legs, or back | |||||
|
| |||||
| Yes | 4.10 (2.71–6.20) | <.001 | 3.73 (2.36–5.92) | <.001 | |
|
| |||||
| No | Ref | Ref | |||
|
| |||||
| Prolonged pain in arms, legs, or back | |||||
|
| |||||
| Yes | 3.35 (2.36–4.76) | <.001 | 4.28 (2.87–6.38) | <.001 | |
|
| |||||
| No | Ref | Ref | |||
|
| |||||
| Weakness or inability to move arm(s) | |||||
|
| |||||
| Yes | 12.36 (7.70–19.84) | <.001 | 7.12 (3.81–13.29) | <.001 | |
|
| |||||
| No | Ref | Ref | |||
|
| |||||
| Weakness or inability to move legs | |||||
|
| |||||
| Yes | 14.19 (8.86–22.75) | <.001 | 12.06 (7.13–20.37) | <.001 | |
|
| |||||
| No | Ref | Ref | |||
|
| |||||
| ≥2 of 5 symptoms, N 1 | |||||
|
| |||||
| Yes | 6.54 (4.50–9.51) | <.001 | 5.24 (3.45–7.95) | <.001 | |
|
| |||||
| No | Ref | Ref | |||
1
PN: For the current analysis, we defined our outcome as having clinical ascertainment of either PSN or PMN. The model was adjusted for age at assessment and race.
<: less than; ≥: more than or equal to; %: percent; CI: Confidence Interval; N: number; P: probability; PN: Peripheral Neuropathy; PMN: Clinically ascertained peripheral motor neuropathy; PRR: Prevalence Rate Ratio; PSN: Clinically ascertained peripheral sensory neuropathy; Ref: Reference